Welcome to our dedicated page for YARROW BIOSCIENCE news (Ticker: YARW), a resource for investors and traders seeking the latest updates and insights on YARROW BIOSCIENCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect YARROW BIOSCIENCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of YARROW BIOSCIENCE's position in the market.
Yarrow Bioscience (YARW) priced a previously announced underwritten public offering of 5,769,231 common shares at $26.00 per share, for expected gross proceeds of approximately $150 million before fees and expenses. The offering is expected to close on September 14, 2026, subject to customary closing conditions.
The company granted underwriters a 30-day option to purchase up to an additional 865,384 shares at the same public price, less underwriting discounts and commissions. All shares in the transaction are being sold by Yarrow.
Yarrow plans to use the net proceeds to fund research and development for its pipeline, including YB-101 for autoimmune thyroid diseases, and for general corporate purposes such as working capital and capital expenditures. Jefferies, TD Cowen and Guggenheim Securities are joint book-running managers, and LifeSci Capital is lead manager. The shares are being offered under an effective shelf registration statement on Form S-3.
Yarrow Bioscience (YARW) has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common stock.
The company expects to grant underwriters a 30-day option to buy up to an additional 15% of common shares at the public offering price, less underwriting discounts and commissions. All securities in the deal are offered by Yarrow. The offering’s completion, size and terms remain subject to market and other conditions. Yarrow plans to use net proceeds to fund research and development for its pipeline and for general corporate purposes. Jefferies, TD Cowen and Guggenheim Securities are joint book-running managers, and LifeSci Capital is lead manager. A shelf registration on Form S-3 was declared effective on August 19, 2026.
Yarrow Bioscience (Nasdaq:YARW) reported second quarter 2026 results and progress on YB-101, its anti-TSHR antibody for Graves’ disease (GD) and thyroid eye disease (TED). The FDA granted Fast Track designation for YB-101 in GD, and a randomized Phase 2a/2b trial in GD (with or without TED) has been initiated, with 32 patients planned in Phase 2a and topline data expected in the second half of 2027. Licensing partner GenSci continues a Phase 1 MAD study in TED in China, with data anticipated in the second half of 2027.
The company completed its reverse merger with VYNE Therapeutics, closed previously announced private financings totaling approximately $200 million, and began trading on Nasdaq as “YARW.” As of June 30, 2026, cash and cash equivalents were $18.7 million; together with $100 million received in July 2026, Yarrow expects to fund operations into 2028. Second quarter 2026 R&D expenses were $4.9 million, G&A expenses were $1.8 million, and net loss was $6.5 million. Following the merger, Yarrow has approximately 28.6 million common shares and equivalents outstanding.
Yarrow Bioscience (Nasdaq: YARW) completed its merger with VYNE Therapeutics and closed previously announced private financings totaling approximately $200 million, which are expected to fund operations into 2028. The combined company will operate as Yarrow Bioscience and its common stock is expected to begin trading on the Nasdaq Capital Market on July 28, 2026 under ticker YARW.
Yarrow’s lead asset YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves’ disease (GD) and thyroid eye disease (TED), has begun dosing in a randomized Phase 2a/2b GD trial after receiving FDA Fast Track Designation. Phase 2a data are expected in 2H 2027, with a Phase 2b dose-finding part anticipated to start in 1H 2028. Partner GenSci is running Phase 1 SAD/MAD trials in TED and GD in China; SAD TED data showed dose-dependent proof-of-mechanism and favorable safety, enabling MAD and Yarrow’s Phase 2a/2b trial. Following a 1-for-50 VYNE reverse stock split and merger, the combined company has about 2.8 million shares outstanding, or 33.6 million fully diluted, and a new CUSIP of 92941V407.